Moldasheva Aiman, Zhakupova Assem, Aljofan Mohamad
Department of Biomedical Sciences, School of Medicine Nazarbayev University, Astana 010000, Kazakhstan.
Laboratory of Drug Discovery and Development, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
Int J Mol Sci. 2024 Dec 30;26(1):247. doi: 10.3390/ijms26010247.
Metformin is an antidiabetic drug with reported potential antiproliferative activity against different cancer types including breast cancer. However, the mechanism of action of how metformin can induce its antiproliferative activity is still unclear. Thus, the current study is a systematic review of the literature aiming to explore the reported antiproliferative mechanisms of metformin against breast cancer. The study included seventeen research articles that describe different mechanisms of action against breast cancer. While the majority of the studies confirm the antiproliferative potential of metformin, albeit at different potencies, there appear to be various mechanisms and factors that can influence this effect. There are a number of questions yet to be answered pertaining the use of metformin as an anti-cancer agent, warranting further investigation into this emerging area of research.
二甲双胍是一种抗糖尿病药物,据报道对包括乳腺癌在内的不同癌症类型具有潜在的抗增殖活性。然而,二甲双胍如何诱导其抗增殖活性的作用机制仍不清楚。因此,本研究是一项系统的文献综述,旨在探讨已报道的二甲双胍对乳腺癌的抗增殖机制。该研究纳入了17篇描述针对乳腺癌不同作用机制的研究文章。虽然大多数研究证实了二甲双胍的抗增殖潜力,尽管效力不同,但似乎有多种机制和因素会影响这种效果。关于将二甲双胍用作抗癌药物仍有许多问题有待解答,这值得对这一新兴研究领域进行进一步调查。